The Experts below are selected from a list of 2472 Experts worldwide ranked by ideXlab platform

Paul T Heath - One of the best experts on this subject based on the ideXlab platform.

  • safety and efficacy of 2 chlorhexidine gluconate aqueous versus 2 chlorhexidine gluconate in 70 isopropyl alcohol for skin disinfection prior to percutaneous central venous catheter insertion in preterm neonates the arctic randomised controlled feasibility trial protocol
    BMJ Open, 2019
    Co-Authors: Paul Clarke, Jean V Craig, John Wain, Catherine Tremlett, Louise Linsell, Ursula Bowler, Ed Juszczak, Paul T Heath
    Abstract:

    Introduction Catheter-related sepsis is one of the most dangerous complications of neonatal intensive care and is associated with significant morbidity and mortality. Use of catheter-care ‘bundles’ has reduced the incidence of catheter-related sepsis, although individual components have not been well studied. Better evidence is needed to guide selection of the most appropriate Antiseptic Solution for skin disinfection in preterm neonates. This study will inform the feasibility and design of the first randomised controlled trial to examine the safety and efficacy of alcohol-based versus aqueous-based chlorhexidine Antiseptic formulations for skin disinfection prior to percutaneous central venous catheterisation in preterm neonates. The Antiseptics to be compared are 2% chlorhexidine gluconate (CHG) aqueous and 2% CHG in 70% isopropyl alcohol. Methods and analysis The Antiseptic Randomised Controlled Trial for Insertion of Catheters (ARCTIC) is a two-centre randomised-controlled feasibility trial. At least 100 preterm infants born at Ethics and dissemination ARCTIC has been approved by the National Health Service Health Research Authority National Research Ethics Service Committee East of England (Cambridge South) (IRAS ID 163868), was adopted onto the National Institute of Health Research Clinical Research Network portfolio (CPMS ID 19899) and is registered with an International Standard Randomised Control Trials Number (ISRCTN: 82571474; Pre-results) and European Clinical Trials Database number 2015-000874-36. Dissemination plans include presentations at scientific conferences, scientific publications and sharing of the findings with parents via the support of Bliss baby charity. Trial registration number ISRCTN82571474; Pre-results.

Maren Eggers - One of the best experts on this subject based on the ideXlab platform.

  • povidone iodine demonstrates rapid in vitro virucidal activity against sars cov 2 the virus causing covid 19 disease
    Infectious Diseases and Therapy, 2020
    Co-Authors: Danielle E Anderson, Velraj Sivalingam, Adrian Eng Zheng Kang, Abhishek Ananthanarayanan, Harsha Arumugam, Timothy M Jenkins, Yacine Hadjiat, Maren Eggers
    Abstract:

    As of 22 June 2020, Severe Acute Respiratory Syndrome (SARS)-coronavirus (CoV)-2 has infected more than 8.95 million people worldwide, causing > 468,000 deaths. The virus is transmitted through respiratory droplets and physical contact from contaminated surfaces to the mucosa. Hand hygiene and oral decontamination among other measures are key to preventing the spread of the virus. We report the in vitro virucidal activity of topical and oral povidone-iodine (PVP-I) products against SARS-CoV-2. Suspension assays were used to assess the virucidal activity of PVP-I against SARS-CoV-2. Products were tested at a contact time of 30 s for virucidal activity. Viral titres were calculated using the Spearman–Karber method and reported as median tissue culture infectious dose (TCID50)/mL. All four products [Antiseptic Solution (PVP-I 10%), skin cleanser (PVP-I 7.5%), gargle and mouth wash (PVP-I 1%) and throat spray (PVP-I 0.45%)] achieved ≥ 99.99% virucidal activity against SARS-CoV-2, corresponding to ≥ 4 log10 reduction of virus titre, within 30 s of contact. This study provides evidence of rapid and effective virucidal activity of PVP-I against SARS-CoV-2. PVP-I-based products are widely available for medical and personal use for hand hygiene and oral decontamination, and could be readily integrated into coronavirus disease, COVID-19, infection control measures in hospital and community settings.

  • Povidone-Iodine Demonstrates Rapid In Vitro Virucidal Activity Against SARS-CoV-2, The Virus Causing COVID-19 Disease
    Infectious Diseases and Therapy, 2020
    Co-Authors: Danielle E Anderson, Velraj Sivalingam, Adrian Eng Zheng Kang, Abhishek Ananthanarayanan, Harsha Arumugam, Timothy M Jenkins, Yacine Hadjiat, Maren Eggers
    Abstract:

    Introduction As of 22 June 2020, Severe Acute Respiratory Syndrome (SARS)-coronavirus (CoV)-2 has infected more than 8.95 million people worldwide, causing > 468,000 deaths. The virus is transmitted through respiratory droplets and physical contact from contaminated surfaces to the mucosa. Hand hygiene and oral decontamination among other measures are key to preventing the spread of the virus. We report the in vitro virucidal activity of topical and oral povidone-iodine (PVP-I) products against SARS-CoV-2. Methods Suspension assays were used to assess the virucidal activity of PVP-I against SARS-CoV-2. Products were tested at a contact time of 30 s for virucidal activity. Viral titres were calculated using the Spearman–Kärber method and reported as median tissue culture infectious dose (TCID_50)/mL. Results All four products [Antiseptic Solution (PVP-I 10%), skin cleanser (PVP-I 7.5%), gargle and mouth wash (PVP-I 1%) and throat spray (PVP-I 0.45%)] achieved ≥ 99.99% virucidal activity against SARS-CoV-2, corresponding to ≥ 4 log_10 reduction of virus titre, within 30 s of contact. Conclusion This study provides evidence of rapid and effective virucidal activity of PVP-I against SARS-CoV-2. PVP-I-based products are widely available for medical and personal use for hand hygiene and oral decontamination, and could be readily integrated into coronavirus disease, COVID-19, infection control measures in hospital and community settings.

Olivier Mimoz - One of the best experts on this subject based on the ideXlab platform.

  • chlorhexidine based Antiseptic Solution vs alcohol based povidone iodine for central venous catheter care
    JAMA Internal Medicine, 2007
    Co-Authors: Olivier Mimoz, Stephanie Villeminey, Stephanie Ragot, Claire Dahyotfizelier, Franck Petitpas, Leila Laksiri, Bertrand Debaene
    Abstract:

    Background Although chlorhexidine-based Solutions and alcohol-based povidone-iodine have been shown to be more efficient than aqueous povidone-iodine for skin disinfection at catheter insertion sites, their abilities to reduce catheter-related infection have never been compared. Methods Consecutively scheduled central venous catheters inserted into jugular or subclavian veins were randomly assigned to be disinfected with 5% povidone-iodine in 70% ethanol or with a combination of 0.25% chlorhexidine gluconate, 0.025% benzalkonium chloride, and 4% benzylic alcohol. Solutions were used for skin disinfection before catheter insertion (2 consecutive 30-second applications separated by a period sufficiently long to allow for dryness) and then as single applications during subsequent dressing changes (every 72 hours, or earlier if soiled or wet). Results Of 538 catheters randomized, 481 (89.4%) produced evaluable culture results. Compared with povidone-iodine, the chlorhexidine-based Solution was associated with a 50% decrease in the incidence of catheter colonization (11.6% vs 22.2% [ P  = .002]; incidence density, 9.7 vs 18.3 per 1000 catheter-days) and with a trend toward lower rates of catheter-related bloodstream infection (1.7% vs 4.2% [ P  = .09]; incidence density, 1.4 vs 3.4 per 1000 catheter-days). Independent risk factors for catheter colonization were catheter insertion into the jugular vein (adjusted relative risk, 2.01; 95% confidence interval, 1.24-3.24) and use of povidone-iodine (adjusted relative risk, 1.87; 95% confidence interval, 1.18-2.96).  Conclusion Chlorhexidine-based Solutions should be considered as a replacement for povidone-iodine (including alcohol-based) formulations in efforts to prevent catheter-related infection. Trial Registration clinicaltrials.gov Identifier:NCT00259350

  • prospective randomized trial of two Antiseptic Solutions for prevention of central venous or arterial catheter colonization and infection in intensive care unit patients
    Critical Care Medicine, 1996
    Co-Authors: Olivier Mimoz, Laurence Pieroni, C Lawrence, A Edouard, Y Costa, K Samii, Christian Brunbuisson
    Abstract:

    Objectives To compare the efficacy of a newly available Antiseptic Solution (composed of 0.25% chlorhexidine gluconate, 0.025% benzalkonium chloride, and 4% benzyl alcohol), with 10% povidone iodine, on the prevention of central venous or arterial catheter colonization and infection.Design Prospecti

Paul Clarke - One of the best experts on this subject based on the ideXlab platform.

  • safety and efficacy of 2 chlorhexidine gluconate aqueous versus 2 chlorhexidine gluconate in 70 isopropyl alcohol for skin disinfection prior to percutaneous central venous catheter insertion in preterm neonates the arctic randomised controlled feasibility trial protocol
    BMJ Open, 2019
    Co-Authors: Paul Clarke, Jean V Craig, John Wain, Catherine Tremlett, Louise Linsell, Ursula Bowler, Ed Juszczak, Paul T Heath
    Abstract:

    Introduction Catheter-related sepsis is one of the most dangerous complications of neonatal intensive care and is associated with significant morbidity and mortality. Use of catheter-care ‘bundles’ has reduced the incidence of catheter-related sepsis, although individual components have not been well studied. Better evidence is needed to guide selection of the most appropriate Antiseptic Solution for skin disinfection in preterm neonates. This study will inform the feasibility and design of the first randomised controlled trial to examine the safety and efficacy of alcohol-based versus aqueous-based chlorhexidine Antiseptic formulations for skin disinfection prior to percutaneous central venous catheterisation in preterm neonates. The Antiseptics to be compared are 2% chlorhexidine gluconate (CHG) aqueous and 2% CHG in 70% isopropyl alcohol. Methods and analysis The Antiseptic Randomised Controlled Trial for Insertion of Catheters (ARCTIC) is a two-centre randomised-controlled feasibility trial. At least 100 preterm infants born at Ethics and dissemination ARCTIC has been approved by the National Health Service Health Research Authority National Research Ethics Service Committee East of England (Cambridge South) (IRAS ID 163868), was adopted onto the National Institute of Health Research Clinical Research Network portfolio (CPMS ID 19899) and is registered with an International Standard Randomised Control Trials Number (ISRCTN: 82571474; Pre-results) and European Clinical Trials Database number 2015-000874-36. Dissemination plans include presentations at scientific conferences, scientific publications and sharing of the findings with parents via the support of Bliss baby charity. Trial registration number ISRCTN82571474; Pre-results.

Ed Juszczak - One of the best experts on this subject based on the ideXlab platform.

  • safety and efficacy of 2 chlorhexidine gluconate aqueous versus 2 chlorhexidine gluconate in 70 isopropyl alcohol for skin disinfection prior to percutaneous central venous catheter insertion in preterm neonates the arctic randomised controlled feasibility trial protocol
    BMJ Open, 2019
    Co-Authors: Paul Clarke, Jean V Craig, John Wain, Catherine Tremlett, Louise Linsell, Ursula Bowler, Ed Juszczak, Paul T Heath
    Abstract:

    Introduction Catheter-related sepsis is one of the most dangerous complications of neonatal intensive care and is associated with significant morbidity and mortality. Use of catheter-care ‘bundles’ has reduced the incidence of catheter-related sepsis, although individual components have not been well studied. Better evidence is needed to guide selection of the most appropriate Antiseptic Solution for skin disinfection in preterm neonates. This study will inform the feasibility and design of the first randomised controlled trial to examine the safety and efficacy of alcohol-based versus aqueous-based chlorhexidine Antiseptic formulations for skin disinfection prior to percutaneous central venous catheterisation in preterm neonates. The Antiseptics to be compared are 2% chlorhexidine gluconate (CHG) aqueous and 2% CHG in 70% isopropyl alcohol. Methods and analysis The Antiseptic Randomised Controlled Trial for Insertion of Catheters (ARCTIC) is a two-centre randomised-controlled feasibility trial. At least 100 preterm infants born at Ethics and dissemination ARCTIC has been approved by the National Health Service Health Research Authority National Research Ethics Service Committee East of England (Cambridge South) (IRAS ID 163868), was adopted onto the National Institute of Health Research Clinical Research Network portfolio (CPMS ID 19899) and is registered with an International Standard Randomised Control Trials Number (ISRCTN: 82571474; Pre-results) and European Clinical Trials Database number 2015-000874-36. Dissemination plans include presentations at scientific conferences, scientific publications and sharing of the findings with parents via the support of Bliss baby charity. Trial registration number ISRCTN82571474; Pre-results.

  • Safety and efficacy of 2% chlorhexidine gluconate aqueous versus 2% chlorhexidine gluconate in 70% isopropyl alcohol for skin disinfection prior to percutaneous central venous catheter insertion in preterm neonates: the ARCTIC randomised-controlled feasib
    'BMJ', 2019
    Co-Authors: Clarke Paul, Ed Juszczak, Craig Jean, Wain John, Tremlett Catherine, Linsell Louise, Bowler Ursula, Heath, Paul T
    Abstract:

    Introduction Catheter-related sepsis is one of the most dangerous complications of neonatal intensive care and is associated with significant morbidity and mortality. Use of catheter-care ‘bundles’ has reduced the incidence of catheter-related sepsis, although individual componentshave not been well studied. Better evidence is needed to guide selection of the most appropriate Antiseptic Solution for skin disinfection in preterm neonates.This study will inform the feasibility and design of the first randomised controlled trial to examine the safety and efficacy of alcohol-based versus aqueous-based chlorhexidine Antiseptic formulations for skin disinfection prior to percutaneous central venous catheterisation in preterm neonates. The Antiseptics to be compared are 2% chlorhexidine gluconate (CHG) aqueous and 2% CHG in 70% isopropyl alcohol.Methods and analysis The Antiseptic Randomised Controlled Trial for Insertion of Catheters (ARCTIC) is a two-centre randomised-controlled feasibility trial. At least 100 preterm infants born at less than 34 weeks’ gestation and due to undergo percutaneous insertion of a centralvenous catheter will be randomly allocated to receive prior skin disinfection with one of the two Antiseptic Solutions. Outcomes include: i) recruitment and retention rates; ii) completeness of data collection; iii) numbers of enrolled infants meeting case definitions for definite catheterrelated sepsis, catheter-associated sepsis and catheter colonisation and iv) safety outcomes of skin morbidity scores recorded daily from catheter insertion until 48 hours post removal. The key feasibility metrics will be reported as proportions with 95% CIs. Estimated prevalence of catheter colonisation will allow calculation of sample size for the large-scale trial. The data will inform whether it will be feasible to progress to a large-scale trial